



FOR IMMEDIATE RELEASE

February 9, 2005

**DALE A. SANDER JOINS BIOLEX AS CHIEF FINANCIAL OFFICER
AND SENIOR VICE PRESIDENT**

PITTSBORO, NC, FEBRUARY 9, 2005: Biolex, Inc., a privately held protein therapeutics company, announced today the appointment of Dale A. Sander as Chief Financial Officer and Senior Vice President, Finance. Mr. Sander brings to Biolex more than 20 years of financial management experience with both private and public life science companies including financial strategies, accounting and SEC reporting.

“Dale has demonstrated significant skill in leading life science companies through periods of substantial growth and change, making him a great fit with the challenges and opportunities now facing Biolex,” said Jan Turek, President and CEO of Biolex. “He is joining us at a key time as we continue to expand our pharmaceutical partnerships and begin clinical trials with the first protein produced in the LEX System™. Our Board and management team anticipate that Dale will be a tremendous asset to Biolex.”

Mr. Sander most recently served as Chief Financial Officer and Vice President of Corporate Development of Maxim Pharmaceuticals, Inc., where he directed public and private financing transactions in the U.S. and Europe, was responsible for a series of pharmaceutical alliances, and led the finance team through periods of substantial growth and change. His earlier career included Chief Financial Officer positions at Xytronyx, Inc., a public biotech company, and Tactyl Technologies, Inc., a medical device manufacturer. Mr. Sander is a Certified Public Accountant and was a Senior Manager with Ernst & Young. He received his B.S. in Business Administration from San Diego State University.

About Biolex: Biolex, Inc. is a private, venture capital-backed biopharmaceutical company. Biolex is developing recombinant human therapeutic proteins that, until now, have been impossible or very expensive to develop in existing expression systems. Biolex’ proprietary LEX System has demonstrated speed, regulatory and economic benefits with hard-to-make proteins and monoclonal antibodies. Biolex has a pipeline of proprietary products in development and its lead candidate, BLX-883, is currently in a Phase 1 clinical trial. Biolex also is partnering with pharmaceutical and biotechnology companies seeking the protein development and production benefits the LEX System offers. Biolex has entered into corporate partnerships with Centocor, Inc., Medarex, Inc., and other pharmaceutical/biotechnology companies. The Company’s headquarters, research laboratories and clinical manufacturing facilities are based in Pittsboro, North Carolina. Visit the Company’s web site at www.biolex.com.

Contact: John Irick, Senior Vice President and Chief Business Officer, 919-542-9901; Michelle Linn, Linnden Communications, 508-869-0138, michlinn@charter.net

###



158 Credle Street
Pittsboro, NC 27312
www.biolex.com

tel 919.542.9901
fax 919.542.9910